M&A Deal Summary |
|
|---|---|
| Date | 2021-06-28 |
| Target | DNA Diagnostics Center |
| Sector | Life Science |
| Buyer(s) | Eurofins Scientific |
| Sellers(s) |
GHO Capital Partners
Goldman Sachs Merchant Banking |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Employees | 51,516 |
| Revenue | 5.4B EUR (2020) |
Eurofins Scientific is an international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments. Eurofins Scientific was incorporated in 1987 and is based in Luxembourg City, Luxembourg.
| DEAL STATS | # |
|---|---|
| Overall | 87 of 95 |
| Sector (Life Science) | 65 of 72 |
| Type (Add-on Acquisition) | 64 of 71 |
| State (Ohio) | 2 of 2 |
| Country (United States) | 28 of 30 |
| Year (2021) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-18 |
Beacon Discovery
San Diego, California, United States Beacon Discovery is a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research. GPCRs provide unexploited opportunities to develop novel drugs addressing significant unmet medical needs. In addition, Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small-molecule modulators as well as its wealth of GPCR discovery skills and tools. Beacon Discovery was founded in 2016 and is based in San Diego, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-10 |
G Lab
Hokkaido , Japan G Lab is a molecular biology-based testing provider for diagnostics, biomarker development, and drug discovery. G Lab has developed a reputation among clinical communities in Japan for the CAP-accredited quality services provided by its technical experts, in-house medical pathologists, and cytotechnologists. G Lab was established in 2000 and is based in Hokkaido, Japan. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2014 |
| PE ASSETS | 5.0B EUR |
| Size | Large |
| Type | Sector Focused |
GHO Capital Partners is a private investment firm focused on the healthcare sector. The Firm will consider opportunities throughout Europe and seeks well-established, profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. GHO Capital Partners was established in 2014 and is based in London.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector (Life Science) | 3 of 3 |
| Type (Add-on Acquisition) | 1 of 1 |
| State (Ohio) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2021) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-08 |
Velocity Clinical Research
Durham, North Carolina, United States Velocity Clinical Research is an integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. Velocity Clinical Research was founded in 2017 and is based in Durham, North Carolina. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-10-26 |
Sanner
Bensheim, Germany Sanner is a provider of packaging solutions and components for the Pharmaceutical, Diagnostic, Nutraceutical and MedTech industries. Sanner is based in Schillerstrasse, Germany. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1986 |
| PE ASSETS | 155.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
Goldman Sachs Merchant Banking Division is the investment arm of Goldman Sachs. The primary corporate investment group within the Merchant Banking Division is Goldman Sachs' direct investment arm. GS's direct investment arm consists of GS Capital Partners, GS Mezzanine Partners, and GS Growth Partners. GS Capital Partners is the direct corporate equity investment group which seeks LBO, recapitalization, and growth investments to help fund acquisitions, expansions, recapitalizations, restructurings, buyouts, and take privates. GS Capital Partners looks to invest between $50 and $800 million in opportunities in North/South America, Europe, Asia. GS Mezzanine Partners is the junior capital arm of Goldman Sachs. GS Mezzanine looks to invest between $200 million and and $800 million in transactions valued up to $10 billion. Investment proceeds are used to fund leveraged buyouts, expansion financings, recapitalizations, acquisitions, and restructurings. GS Growth looks to invest in growth equity transactions. The unit seeks to commit $20 to $200 million per investment. Other units within GS's merchant banking division include Real Estate, Infrastructure, and Urban Investments. Goldman Sachs Merchant Banking Division is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 98 of 108 |
| Sector (Life Science) | 1 of 2 |
| Type (Add-on Acquisition) | 32 of 36 |
| State (Ohio) | 5 of 5 |
| Country (United States) | 71 of 77 |
| Year (2021) | 9 of 15 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-24 |
Navico
Tulsa, Oklahoma, United States Navico is a provider in marine electronics for the recreational segment and is an innovative force within the commercial marine market. Navico offers multi-function displays, fish finders, autopilots, sonar, radar, and cartography. Navico strong brands serve most major powerboat and sailing markets for both recreational and commercial applications. Navico was founded in 2006 and is based in Tulsa, Oklahoma. |
Sell | $1.1B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-02 |
Parexel
Durham, North Carolina, United States Parexel is a global provider of clinical research and consulting services to the pharma and biotech industry. Parexel’s services enable the development of innovative new medicines that improve the health of patients across the world. Parexel was founded in 1983 and is based in Durham, North Carolina. |
Buy | $8.5B |
